Now livetag icon
Who's really winning the World Cup economy? The data is in!Get the snapshotbanner icon
Bioheng

June 2026

Bioheng Market Share Analysis for June 2026

Bioheng Therapeutics Search Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T.
Industry: N/A
Year Founded2017
Employees51 - 200
Annual Revenue--
bioheng.com
Bioheng
Bioheng (including company regionals)
  • bioheng.com
    bioheng.com
See more website traffic and engagement information

Total visits to Bioheng's top domains

Understand Bioheng market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in Bioheng's top domains

Analyze Bioheng engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on Bioheng's top domains

See how Bioheng keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.


Bioheng top competitors by domain

Looks like there’s not enough data here

No Data to Display

Benchmark Your Digital Performance

Identify high-value opportunities, track your performance, and win your market.


Top technologies used by Bioheng

These are the website technologies, by industry, used by Bioheng top domains

Mobile (3)

Meta Viewport

Meta Viewport

Email Services (2)

Microsoft Exchange Online

Microsoft Exchange Online

Widget (2)

General Captcha

General Captcha

Advertising (1)

PubMatic

PubMatic

More Technologies

1

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from Bioheng

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBioheng Biotech Co., Ltd launches CTD402.At this event, Bioheng Therapeutics presented the latest clinical data on its universal CAR-T product, CTD402, for the treatment of patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), in the form of an oral report.
NewsBioheng Biotech Co., Ltd attends event 66th American Society of Hematology (ASH) Annual Meeting.November 7, 2024, Bioheng Therapeutics (referred to as "Bioheng"), an innovative biopharmaceutical company dedicated to the development and commercialization of cell therapy products, announced today that it will present the latest Phase I clinical data of its universal CAR-T cell product RD13-02, targeting CD7 for the treatment of relapsed/refractory(R/R) T-ALL/LBL patients, in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting.

See all Bioheng signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.